©Reuters.
WALTHAM, Mass. – Biopharmaceutical company Invivid, Inc. (NASDAQ:IVVD) announced its Phase 3 CANOPY clinical trial for VYD222, an investigational monoclonal antibody for pre-exposure prophylaxis of coronavirus disease (COVID-19). We announced interim exploratory data from the exam.
This study aims to understand the relationship between serum virus-neutralizing antibody (sVNA) titers and clinical efficacy, particularly in individuals with prior immunity from vaccination or infection.
The company shared an update on symptomatic coronavirus disease (COVID-19) events up to 90 days, following initial reports in December 2023 suggesting potential for clinical protection. The current findings show that the incidence of symptomatic COVID-19 infection within the non-immunocompromised cohort was 0.3% in the VYD222 group versus 5% in the placebo group. In the immunocompromised cohort, the incidence of VYD222 was 1%.
Although these interim results are not the main focus of the CANOPY trial, they may be useful for future research and development. Invivyd plans to present a more comprehensive analysis at day 180, including a comparison of measured and calculated sVNA titers and their correlation with clinical outcomes.
VYD222 is a neutralizing monoclonal antibody candidate with extended half-life designed to exhibit broad activity against a variety of SARS-CoV-2 variants. It is based on one of Invivyd's investigational antibodies, addintrevimab, which has shown promising results in clinical trials to date.
Invivyd's mission is to provide antibody-based treatments for serious viral diseases, starting with coronavirus disease (COVID-19). The company's proprietary INVYMAB™ platform combines viral surveillance, predictive modeling, and advanced antibody engineering to develop a pipeline of potential therapeutics.
Information in this article is based on Invivyd's press release.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.